This is followed by the release of nesfatin-1 which stimulates cholecystokinin secretion leading to a rise in bile salts from gallbladder emptying, and the binding of Takeda P protein coupled receptor 5 (TGR5) onto the surface of the enteroendocrine cells, all of which eventually culminates in GLP-1 secretion [9]
By combining Peptides injections with a nutritious diet and regular exercise, it is possible to reduce abdominal fat
Schlessinger J, Saxena S, Mohr S
GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally
doi: 10.1158/0008-5472.CAN-09-4672 95 UgelSCanSDe SanctisFBronteV
